Research graph
References from Pharmacogenomics-guided therapy for essential hypertension: a multi-center randomized controlled open-label trial. Local targets link to admitted publications; unresolved targets remain external evidence.
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s0140-6736(18)32203-7 · 2018 · External reference
Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries
10.1161/circulationaha.115.018912 · 2016 · External reference
Hypertension in low- and middle-income countries
10.1161/circresaha.120.318729 · 2021 · External reference
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
10.1161/hyp.0000000000000066 · 2018 · External reference
The hypertension paradox–more uncontrolled disease despite improved therapy
10.1056/nejmsa0903829 · 2009 · External reference
Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine
10.1002/wsbm.1173 · 2012 · External reference
Pharmacogenetics, pharmacogenomics, and individualized medicine
10.1124/pr.110.003533 · 2011 · External reference
Computational and pharmacogenomic insights on hypertension treatment: rational drug design and optimization strategies
10.2174/1389450120666190808101356 · 2019 · External reference
CYP2D6 Genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
10.1016/j.annonc.2021.07.005 · 2021 · External reference
Treatment for resistant hypertension under the guidance of pharmacogenomics: a randomised controlled open-label trial
10.29271/jcpsp.2024.04.383 · 2024 · External reference
Lack of association of the angiotensin converting enzyme polymorphism with essential hypertension in a Chinese population
10.1016/s0895-7061(96)00345-7 · 1997 · External reference
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
10.1172/jci114844 · 1990 · External reference
Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene among malay male hypertensive subjects in response to ACE inhibitors
10.1177/1470320314538878 · 2015 · External reference
Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism
10.1023/a:1007820401377 · 2000 · External reference
Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: m-mode and pulsed Doppler echocardiographic studies
10.1097/00004872-199612000-00003 · 1996 · External reference
Distributive characteristics of the CYP2C9 and AGTR1 genetic polymorphisms in han Chinese hypertensive patients: a retrospective study
10.1186/s12872-021-01895-w · 2021 · External reference
Association of cytochrome P450 2C9*3 and angiotensin II receptor 1 (1166A > C) gene polymorphisms with the antihypertensive effect of irbesartan
10.1093/ajh/hpaa134 · 2021 · External reference
Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions
10.1038/clpt.2010.315 · 2011 · External reference
S49g and R389G polymorphisms of the β₁-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways
10.1152/physiolgenomics.00087.2013 · 2013 · External reference
Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension
10.1177/0300060514563151 · 2015 · External reference
Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation
10.1124/dmd.113.055400 · 2014 · External reference
CYP3A4 And CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease
10.1159/000258688 · 2010 · External reference
CACNA1C Polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension
10.2217/14622416.7.3.271 · 2006 · External reference
Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension
10.1016/s0140-6736(97)01029-5 · 1997 · External reference
Alpha-Adducin 460Trp allele is associated with erythrocyte na transport rate in north sardinian primary hypertensives
10.1161/hy0202.103065 · 2002 · External reference
Personalized antihypertensive treatment guided by pharmacogenomics in China
10.21037/cdt-22-154 · 2022 · External reference
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese
10.1161/01.cir.90.5.2199 · 1994 · External reference
ACE Insertion/deletion polymorphism is positively associated with resistant hypertension in Morocco
10.1016/j.gene.2018.03.028 · 2018 · External reference
Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy
10.1056/nejm199406093302302 · 1994 · External reference
The angiotensin-I-converting enzyme insertion/deletion in polymorphic element codes for an AluYa5 RNA that downregulates gene expression
10.1038/s41397-018-0020-x · 2018 · External reference
Mathematical modelling of the influence of ACE I/D polymorphism on blood pressure and antihypertensive therapy
10.1016/j.heliyon.2024.e29988 · 2024 · External reference
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study
10.1097/fpc.0b013e328333f70b · 2010 · External reference
Association of polymorphisms of CYP11B2 gene −344C/T and ACE gene I/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension
10.1007/s12041-018-1053-2 · 2019 · External reference
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants
10.3389/fsysb.2025.1504077 · 2025 · External reference
CYP2C9 Gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study
10.1515/dmpt-2022-0115 · 2023 · External reference
Influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite E-3174: a systematic review and meta-analysis
10.3390/jpm11070617 · 2021 · External reference
CYP2C9 Genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men
10.1097/hjh.0b013e32832f4fae · 2009 · External reference
Lack of effects of renin-angiotensin-aldosterone system activity and beta-adrenoceptor pathway polymorphisms on the response to bisoprolol in hypertension
10.3389/fcvm.2022.842875 · 2022 · External reference
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
10.1046/j.1365-2125.1999.00923.x · 1999 · External reference
The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population
10.1097/01213011-200512000-00001 · 2005 · External reference
CYP3A4*1G And CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
10.5414/cp202559 · 2017 · External reference
CYP3A5 Polymorphism, amlodipine and hypertension
10.1038/jhh.2013.67 · 2014 · External reference
Genetic and phenotypic frequency distribution of ACE, ADRB1, AGTR1, CYP2C9*3, CYP2D6*10, CYP3A5*3, NPPA and factors associated with hypertension in Chinese han hypertensive patients
10.1097/md.0000000000033206 · 2023 · External reference
Lack of association between genetic variations in CYP3A5 and blood pressure or hypertension risk in the UK biobank
10.3389/fgene.2025.1490863 · 2025 · External reference
Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers
10.1253/circj.cj-08-0761 · 2009 · External reference
CACNA1C Gene polymorphisms, cardiovascular disease outcomes, and treatment response
10.1161/circgenetics.109.857839 · 2009 · External reference
Pharmacogenomic study of selected genes affecting amlodipine blood pressure response in patients with hypertension
10.2147/pgpm.s481068 · 2024 · External reference
Pharmacogenomic insights into amlodipine response: the role of CACNA1D, CACNA1C, and TRIB3 variants in hypertensive patients
10.1371/journal.pone.0329263 · 2025 · External reference
Associations of variants in the CACNA1A and CACNA1C genes with longitudinal blood pressure changes and hypertension incidence: the GenSalt study
10.1093/ajh/hpw070 · 2016 · External reference
ACE And alpha-adducin polymorphism as markers of individual response to diuretic therapy
10.1161/01.hyp.0000057010.27011.2c · 2003 · External reference
Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis
10.5414/cp201899 · 2013 · External reference
Association of α-adducin and G-protein β3 genetic polymorphisms with hypertension: a meta-analysis of Chinese populations
10.1371/journal.pone.0017052 · 2011 · External reference
Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation
10.1161/hypertensionaha.108.113977 · 2008 · External reference
Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine
10.1002/wsbm.1173 · ExternalCitation · doi-reference
Association of polymorphisms of CYP11B2 gene −344C/T and ACE gene I/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension
10.1007/s12041-018-1053-2 · ExternalCitation · doi-reference
CYP2D6 Genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
10.1016/j.annonc.2021.07.005 · ExternalCitation · doi-reference
ACE Insertion/deletion polymorphism is positively associated with resistant hypertension in Morocco
10.1016/j.gene.2018.03.028 · ExternalCitation · doi-reference
Mathematical modelling of the influence of ACE I/D polymorphism on blood pressure and antihypertensive therapy
10.1016/j.heliyon.2024.e29988 · ExternalCitation · doi-reference
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s0140-6736(18)32203-7 · ExternalCitation · doi-reference
Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension
10.1016/s0140-6736(97)01029-5 · ExternalCitation · doi-reference
Lack of association of the angiotensin converting enzyme polymorphism with essential hypertension in a Chinese population
10.1016/s0895-7061(96)00345-7 · ExternalCitation · doi-reference
Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism
10.1023/a:1007820401377 · ExternalCitation · doi-reference
Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions
10.1038/clpt.2010.315 · ExternalCitation · doi-reference
CYP3A5 Polymorphism, amlodipine and hypertension
10.1038/jhh.2013.67 · ExternalCitation · doi-reference
The angiotensin-I-converting enzyme insertion/deletion in polymorphic element codes for an AluYa5 RNA that downregulates gene expression
10.1038/s41397-018-0020-x · ExternalCitation · doi-reference
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
10.1046/j.1365-2125.1999.00923.x · ExternalCitation · doi-reference
Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy
10.1056/nejm199406093302302 · ExternalCitation · doi-reference
The hypertension paradox–more uncontrolled disease despite improved therapy
10.1056/nejmsa0903829 · ExternalCitation · doi-reference
Association of cytochrome P450 2C9*3 and angiotensin II receptor 1 (1166A > C) gene polymorphisms with the antihypertensive effect of irbesartan
10.1093/ajh/hpaa134 · ExternalCitation · doi-reference
Associations of variants in the CACNA1A and CACNA1C genes with longitudinal blood pressure changes and hypertension incidence: the GenSalt study
10.1093/ajh/hpw070 · ExternalCitation · doi-reference
Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: m-mode and pulsed Doppler echocardiographic studies
10.1097/00004872-199612000-00003 · ExternalCitation · doi-reference
The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population
10.1097/01213011-200512000-00001 · ExternalCitation · doi-reference
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study
10.1097/fpc.0b013e328333f70b · ExternalCitation · doi-reference
CYP2C9 Genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men
10.1097/hjh.0b013e32832f4fae · ExternalCitation · doi-reference
Genetic and phenotypic frequency distribution of ACE, ADRB1, AGTR1, CYP2C9*3, CYP2D6*10, CYP3A5*3, NPPA and factors associated with hypertension in Chinese han hypertensive patients
10.1097/md.0000000000033206 · ExternalCitation · doi-reference
Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation
10.1124/dmd.113.055400 · ExternalCitation · doi-reference
Pharmacogenetics, pharmacogenomics, and individualized medicine
10.1124/pr.110.003533 · ExternalCitation · doi-reference
S49g and R389G polymorphisms of the β₁-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways
10.1152/physiolgenomics.00087.2013 · ExternalCitation · doi-reference
CYP3A4 And CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease
10.1159/000258688 · ExternalCitation · doi-reference
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese
10.1161/01.cir.90.5.2199 · ExternalCitation · doi-reference
ACE And alpha-adducin polymorphism as markers of individual response to diuretic therapy
10.1161/01.hyp.0000057010.27011.2c · ExternalCitation · doi-reference
CACNA1C Gene polymorphisms, cardiovascular disease outcomes, and treatment response
10.1161/circgenetics.109.857839 · ExternalCitation · doi-reference
Hypertension in low- and middle-income countries
10.1161/circresaha.120.318729 · ExternalCitation · doi-reference
Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries
10.1161/circulationaha.115.018912 · ExternalCitation · doi-reference
Alpha-Adducin 460Trp allele is associated with erythrocyte na transport rate in north sardinian primary hypertensives
10.1161/hy0202.103065 · ExternalCitation · doi-reference
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
10.1161/hyp.0000000000000066 · ExternalCitation · doi-reference
Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation
10.1161/hypertensionaha.108.113977 · ExternalCitation · doi-reference
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
10.1172/jci114844 · ExternalCitation · doi-reference
Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension
10.1177/0300060514563151 · ExternalCitation · doi-reference
Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene among malay male hypertensive subjects in response to ACE inhibitors
10.1177/1470320314538878 · ExternalCitation · doi-reference
Distributive characteristics of the CYP2C9 and AGTR1 genetic polymorphisms in han Chinese hypertensive patients: a retrospective study
10.1186/s12872-021-01895-w · ExternalCitation · doi-reference
Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers
10.1253/circj.cj-08-0761 · ExternalCitation · doi-reference
Association of α-adducin and G-protein β3 genetic polymorphisms with hypertension: a meta-analysis of Chinese populations
10.1371/journal.pone.0017052 · ExternalCitation · doi-reference
Pharmacogenomic insights into amlodipine response: the role of CACNA1D, CACNA1C, and TRIB3 variants in hypertensive patients
10.1371/journal.pone.0329263 · ExternalCitation · doi-reference
CYP2C9 Gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study
10.1515/dmpt-2022-0115 · ExternalCitation · doi-reference
Personalized antihypertensive treatment guided by pharmacogenomics in China
10.21037/cdt-22-154 · ExternalCitation · doi-reference
Pharmacogenomic study of selected genes affecting amlodipine blood pressure response in patients with hypertension
10.2147/pgpm.s481068 · ExternalCitation · doi-reference
Computational and pharmacogenomic insights on hypertension treatment: rational drug design and optimization strategies
10.2174/1389450120666190808101356 · ExternalCitation · doi-reference
CACNA1C Polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension
10.2217/14622416.7.3.271 · ExternalCitation · doi-reference
Treatment for resistant hypertension under the guidance of pharmacogenomics: a randomised controlled open-label trial
10.29271/jcpsp.2024.04.383 · ExternalCitation · doi-reference
Lack of effects of renin-angiotensin-aldosterone system activity and beta-adrenoceptor pathway polymorphisms on the response to bisoprolol in hypertension
10.3389/fcvm.2022.842875 · ExternalCitation · doi-reference
Lack of association between genetic variations in CYP3A5 and blood pressure or hypertension risk in the UK biobank
10.3389/fgene.2025.1490863 · ExternalCitation · doi-reference
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants
10.3389/fsysb.2025.1504077 · ExternalCitation · doi-reference
Influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite E-3174: a systematic review and meta-analysis
10.3390/jpm11070617 · ExternalCitation · doi-reference
Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis
10.5414/cp201899 · ExternalCitation · doi-reference
CYP3A4*1G And CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
10.5414/cp202559 · ExternalCitation · doi-reference
